case-study-page
knowledge

Enable Diabetic Retinal Exams at the Point of Care

Patient receiving diabetic retinal exam

Decreasing Cost of Care and Improving Patient Outcomes

Rendr Care Moves From 2 to 5 Stars for Diabetic Retinopathy Compliance

This primary care organization increased access to diabetic retinopathy exams for patients and achieved a 5-star compliance rating across multiple providers

90%

  

Compliance Burden

Patients living with diabetes should be examined for complications on an annual basis, but only 60% of patients comply.1 Up to 80% of individuals with type two diabetes may develop some stage of diabetic retinopathy. 1 Even though diabetic retinopathy is the leading cause of blindness in adults aged 20 to 742, 95% of vision loss from diabetic retinopathy can be prevented with early detection.3

90%

Providers can achieve up to 90% compliance for diabetic retinopathy exams in 12 months with an effective teleretinal imaging solution.4

  

The Solution is in Sight

What if you could deliver diabetic retinal exams anywhere the patient receives care? Whether you’re performing diabetic retinal exams in the primary care office or in a mobile clinic, including the Welch Allyn RetinaVue care delivery model as part of your comprehensive diabetes management program increases access to care.

RETINAVUE Care Delivery Model

Help preserve the vision of your patients living with diabetes with a simple five-minute eye exam for diabetic retinopathy detection during routine primary care visits.

Simple and Affordable Hardware

Simple and Affordable Hardware

Secure Software Network

Secure Software Network

Nationwide Services and Support

Nationwide Services and Support

Are you ready to help preserve vision for patients living with diabetes? Complete the form to learn about Rendr Care’s story and connect with a rep.

   

References
  1. Diabetic Retinopathy Preferred Practice Pattern® from the American Academy of Ophthalmology, http://dx.doi.org/10.1016/j.ophtha.2019.09.025, ISSN 0161-6420/19. Accessed July 29, 2020.
  2. Centers for Disease Control and Prevention. Vision Health Initiative (VHI). https://www.cdc.gov/visionhealth/basics/ced/ Published September 29, 2015. Updated June 3, 2020. Accessed September 9, 2022.
  3. “New Treatment Options, Better Hope of Preventing Vision Loss from Diabetes | National Eye Institute.” https://www.nei.nih.gov/about/news-and-events/news/new-treatment-options-better-hope-preventing-vision-loss-diabetes. Published November 19, 2015. Accessed September 9, 2022.
  4. Mansberger SL, Sheppler C, Barker G, et al. Long-term comparative effectiveness of telemedicine in providing diabetic retinopathy screening examinations: A randomized clinical trial. JAMA Ophthalmol.
Baxter, Hillrom, RetinaVue and Welch Allyn are trademarks of Baxter International Inc. or its subsidiaries. ALL RIGHTS RESERVED. US-FLC-147-230022 V1 02/23